Pressure BioSciences' Patented PCT Platform Shown to Significantly Improve Protein and DNA Detection in Multiple Studies

Advantages of the PCT Platform Could Potentially Enhance Development of New Products in the Forensic, Environmental, and Biodefense Areas, and in the Discovery of Biomarkers of Disease SOUTH EASTON, Mass., July 18, 2012 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company") today announced that multiple research reports have cited the ability of the Company's Pressure Cycling Technology ("PCT") Platform to improve the detection of RNA, DNA, and/or protein in forens...continued PBIO  pct fractionation financials

URL: http://www.investorpoint.com/news/INTHPINK/52808975/